PDCD1 and cancer: MIR155HG could affect immune checkpoint molecules via mir-155, which suppresses PD-L1, disrupts the PD-L1/PD-1 axis, and maintains T cell antitumor responses, potentially influencing resistance to cancer immunotherapy [26].